Importance of a new tumor market TRA-1-60 in the follow-up of patients with clinical stage I nonseminomatous testicular germ cell tumors

[1]  I. Sesterhenn,et al.  Histological Typing of Testis Tumours , 1998, World Health Organization.

[2]  H. D. de Bruijn,et al.  Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Horwich,et al.  Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Motzer,et al.  Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy , 1994, Cancer.

[5]  M. Gospodarowicz,et al.  Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  平田 章二.  Significance of glutathione S-transferase-π as a tumor marker in patients with oral cancer , 1992 .

[7]  F. Mostofi,et al.  Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Freiha,et al.  Serum markers in germ cell neoplasms. , 1991, Hematology/Oncology Clinics of North America.

[9]  D. Johnson,et al.  Staging and prognostic factors in nonseminomatous testicular cancer. , 1991, Hematology/oncology clinics of North America.

[10]  P. Andrews,et al.  Tra‐1‐60: A new serum marker in patients with germ‐cell tumors , 1991, International journal of cancer.

[11]  O. S. Nielsen,et al.  Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Horwich.  Testicular cancer : investigation and management , 1991 .

[13]  P. Andrews,et al.  The surface antigen phenotype of human embryonal carcinoma cells: modulation upon differentiation and viral infection. , 1991, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[14]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[15]  N. Geller,et al.  Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. , 1990, Cancer research.

[16]  A. Horwich,et al.  The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy. , 1990, European journal of cancer.

[17]  A. Stenwig,et al.  Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Kienzer,et al.  Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Tattersall,et al.  Surveillance for Stage I Non-Seminomatous Germ Cell Tumours of the Testis: The Optimal Protocol has not yet been Defined , 1989 .

[20]  C. Logothetis,et al.  Clinical Stage I Nonseminomatous and Mixed Germ Cell Tumors of the Testis: A Clinicopathologic Study of 93 Patients on a Surveillance Protocol after Orchiectomy Alone , 1989 .

[21]  C. Logothetis,et al.  Clinical stage i nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone , 1988, Cancer.

[22]  M. Tattersall,et al.  Surveillance for stage I non-seminomatous germ cell tumours of the testis: the optimal protocol has not yet been defined. , 1988, British journal of urology.

[23]  F. Mostofi,et al.  Immunopathology of germ cell tumors of the testis. , 1987, Seminars in diagnostic pathology.

[24]  D. Longo,et al.  Use of serum tumor markers in cancer diagnosis and management. , 1987, Seminars in oncology.

[25]  A. Horwich,et al.  Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Whitmore,et al.  Correlation of serum tumor markers in advanced germ cell tumors with responses to chemotherapy and surgery , 1984, Cancer.

[27]  N C Dracopoli,et al.  Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. , 1984, Laboratory investigation; a journal of technical methods and pathology.

[28]  P. Avner,et al.  Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. , 1984, Hybridoma.

[29]  A. Horwich,et al.  Orchiectomy alone for Stage I testicular non-seminoma. A progress report on the Royal Marsden Hospital study. , 1983, British journal of urology.

[30]  P. Wilkinson,et al.  Prospective study of follow up alone in stage I teratoma of the testis. , 1983, British medical journal.

[31]  N. Geller,et al.  Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience. , 1983, The American journal of medicine.

[32]  E. Newlands,et al.  FURTHER ADVANCES IN THE MANAGEMENT OF MALIGNANT TERATOMAS OF THE TESTIS AND OTHER SITES , 1983, The Lancet.

[33]  G. Fleuren,et al.  Effects of multiple‐drug chemotherapy (cis‐diammine‐dichloroplatinum, bleomycin, and vinblastine) on the maturation of retroperitoneal lymph node metastases of nonseminomatous germ cell tumors of the testis: No evidence for de novo induction of differentiation , 1983, Cancer.

[34]  D. Sleijfer,et al.  Non-seminomatous germ cell tumors of the testis. Analysis of AFP and HCG production by primary tumors and retroperitoneal lymph node metastases after PVB combination chemotherapy. , 1983, Oncodevelopmental biology and medicine : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[35]  P. Lange,et al.  Marker half-life analysis as a prognostic tool in testicular cancer. , 1982, The Journal of urology.

[36]  L. Weissbach,et al.  Immunohistochemical localisation of alpha-fetoprotein (AFP) in germ cell tumours: evidence for AFP production by tissues different from endodermal sinus tumour. , 1981, Oncology.

[37]  H. D. de Bruijn,et al.  Tumor markers in patients with non-seminomatous germ cell tumors of the testis. , 1981, Oncodevelopmental biology and medicine : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[38]  A. Barrett,et al.  COMBINED MANAGEMENT OF MALIGNANT TERATOMA OF THE TESTIS , 1979, The Lancet.

[39]  H. Pinedo,et al.  COMBINATION CHEMOTHERAPY WITH CIS-DIAMMINE-DICHLORO-PLATINUM, VINBLASTINE, AND BLEOMYCIN IN ADVANCED TESTICULAR NON-SEMINOMA , 1979, The Lancet.

[40]  M. Harmer.  TNM classification of malignant tumours , 1978 .

[41]  T. Waldmann,et al.  Cellular localization of alpha‐fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using an indirect immunoperoxidase technique. A new approach to classification utilizing tumor markers , 1977 .

[42]  L. Einhorn,et al.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. , 1977, Annals of internal medicine.

[43]  T. Waldmann,et al.  Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using and indirect immunoperoxidase technique. , 1977, Cancer.

[44]  R. Freeman,et al.  Letter: Radioimmunoassay of apo-L.D.L. , 1974, Lancet.

[45]  D Rodbard,et al.  Rapid calculation of radioimmunoassay results. , 1969, The Journal of laboratory and clinical medicine.